334 replies to this topic

[ImmInst]

Interesting Options Volume for Geron Corporation (GERN)
Market Intellisearch - 36 minutes ago

NEW YORK (Market Intellisearch) -- GERN options saw interesting call activity today. A total of 85 put and 2,063 call contracts were traded raising a low Put/Call volume alert. Today's traded Put ...

View the full article

[ImmInst]

Interesting Options Volume for Geron Corporation (GERN)
Market Intellisearch - 4 hours ago

NEW YORK (Market Intellisearch) -- GERN options saw interesting call activity today. A total of 85 put and 2,063 call contracts were traded raising a low Put/Call volume alert. Today's traded Put ...

View the full article

[ImmInst]

Life Technologies Convenes Leadership Summit to Highlight Commercial Achievements in Cell Therapy
Business Wire - 15 hours ago

CARLSBAD, Calif.--(BUSINESS WIRE)--Life Technologies Corporation (NASDAQ:LIFE), a provider of innovative life science solutions, is hosting the 2 nd Annual Cell Therapy Industry Summit November 3 ...

View the full article

[AlleyAllee]

Specially Biotechnology stocks is so important with high benefit. One can easily invest in this.

[ImmInst]

Life Technologies Convenes Leadership Summit to Highlight Commercial Achievements in Cell Therapy
Advertiser Talk - 1 hour ago

Life Technologies Corporation (NASDAQ:LIFE), a provider of innovative life science solutions, is hosting the 2nd Annual Cell Therapy Industry Summit November 3-5 at the Sheraton Carlsbad Resort ...

View the full article

[ImmInst]

Geron Announces Two Publications Demonstrating That Its Telomerase Inhibitor Drug Targets Cancer Stem Cells
Business Wire - 1 hour ago

MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) today announced the publication of preclinical data demonstrating that the company's telomerase inhibitor drug, imetelstat ...

Geron Reveals Publication Of Preclinical Data Regarding Imetelstat - Quick Facts - RTT News
Geron Corp (GERN) Announces Two Publications Showing GRN163L Targets Cancer Stem Cells - StreetInsider.com

View the full article

[ImmInst]

Stem Cell Stocks Movers (GREN, STEM, BTX, CYTX)
Chart Poppers - 37 minutes ago

Geron Corporation (NASDAQ:GERN) rose 4% to $6.03 on over 1.50 million shares after it announced the publication of preclinical data demonstrating that the company's telomerase inhibitor drug ...

View the full article

[ImmInst]

Shares of Geron are Moving Higher on 1.1x Above-Average Volume (GERN)
Benzinga - 2 hours ago

Shares of Geron (NASDAQ: GERN) are trading up 3.3% to $5.99 today on above average volume. Approximately 1.7 million shares have traded hands today vs. average 30-day volume of 1.6 million shares ...

GERON: THE TREND CONTINUES HIGHER (GERN) - Zacks.com

View the full article

[ImmInst]

GERON RISES 4.83% ON HEAVY VOLUME: WATCH FOR POTENTIAL PULLBACK (GERN)
Zacks.com - 1 hour ago

Nov 12, 2010 (SmarTrend® News Watch via COMTEX) -- Geron (NASDAQ:GERN) traded in a range yesterday that spanned from a low of $5.91 to a high of $6.23. Yesterday, the shares gained 4.83%, which ...

View the full article

[ImmInst]

CEO Interview: BioTime, Inc. (BTX) - Dr. Michael D. West
The Wall Street Transcript - 1 hour ago

November 15, 2010 - The Wall Street Transcript has just published Biotechnology & Pharmaceuticals Report offering a timely review of the Biotechnology sector. This Special Report contains expert ...

View the full article

[ImmInst]

Athersys (Nasdaq: ATHX) Secures Multiple Grants to Advance Its Therapeutic Programs
BiotechStockTrader.com - 2 hours ago

By Justin Kuepper on Wednesday, November 17th, 2010 Athersys, Inc. (Nasdaq: ATHX), a clinical-stage biotechnology company focused on its MultiStem technology capable of producing a range of ...

View the full article

[ImmInst]

Feds OK 2nd human study of embryonic stem cells; effort to focus on treating rare eye disease
Los Angeles Times - 6 minutes ago

NEW YORK (AP) — For only the second time, the US government has approved a test in people of a treatment using embryonic stem cells — this time for a rare disease that causes serious vision loss ...

View the full article

[ImmInst]

FDA gives green light to stem cell treatment
KATU - 10 minutes ago

By MALCOLM RITTER AP Science Writer Just last month another biotech company, Geron Corp., said it had begun preliminary testing in people for treating spinal cord injuries by injecting cells ...

View the full article

[ImmInst]

Beacon NewsFlashes – November 22, 2010
The Myeloma Beacon - 3 hours ago

Opinion: Individualizing The Dosing Of Multiple Myeloma Treatment – In the latest article published in the opinion section of The Beacon, Dr. Gary Blau, a multiple myeloma patient and visiting ...

View the full article

[ImmInst]

StarMine 4 - Star Rated Biotech Stock Picker Sees Broader Trend In The Announced Acquisition Of King Pharmaceuticals (KG) By Pfizer (PFE)
The Wall Street Transcript - 1 hour ago

November 24, 2010 - The Wall Street Transcript has just published Biotechnology & Pharmaceuticals Report offering a timely review of the Biotechnology sector. This 81 page feature contains expert ...

View the full article

[ImmInst]

Geron's (NASDAQ: GERN) Fountain of Youth in a Pill
Wealth Daily - 21 minutes ago

By Steve Christ Every morning when my feet hit the floor, I'm hit with the cold, hard truth from the cleat of reality. After a good night's sleep, my body squeaks invariably and groans a bit like ...

View the full article

[ImmInst]

Geron's (NASDAQ: GERN) Fountain of Youth in a Pill
Wealth Daily - 7 hours ago

By Steve Christ Every morning when my feet hit the floor, I'm hit with the cold, hard truth from the cleat of reality. After a good night's sleep, my body squeaks invariably and groans a bit like ...

View the full article

[ImmInst]

Geron Initiates Randomized Phase 2 Clinical Trial of Imetelstat in Breast Cancer
Business Wire - 1 hour ago

MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) today announced enrollment of the first patient in a randomized Phase 2 clinical trial of its telomerase inhibitor drug ...

Geron Begins Randomized Phase 2 Trial Of Imetelstat In Breast Cancer-Quick Facts - RTT News
Geron (GERN) Anounces Inititiation of Imetelstat Phase 2 Trial - StreetInsider.com

View the full article

[ImmInst]

Geron Upward Momentum Looks to Continue (GERN)
Benzinga - 1 hour ago

SmarTrend identified an Uptrend for Geron (NASDAQ: GERN) on September 29, 2010 at $5.52. In approximately 2 months, Geron has returned 8.8% as of today's recent price of $6.00. In the past 52 ...

View the full article

[ImmInst]

Geron starts randomized phase 2 trial of imetelstat in breast cancer
pharmabiz.com - 16 minutes ago

Geron Corporation announced enrolment of the first patient in a randomized phase 2 clinical trial of its telomerase inhibitor drug, imetelstat (GRN163L), in combination with paclitaxel (with or ...

View the full article

[ImmInst]

Geron Presents Clinical Data on Its Telomerase Vaccine at the 2010 American Society of Hematology Meeting
Business Wire - 6 minutes ago

MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (NASDAQ:GERN) today announced the presentation of final data from its Phase 2 clinical trial of GRNVAC1, an autologous dendritic cell vaccine ...

View the full article

[ImmInst]

Shares of Geron are Moving Higher on 1.3x Above-Average Volume (GERN)
Benzinga - 2 hours ago

Shares of Geron (NASDAQ: GERN) are trading up 3% to $6.19 today on above average volume. Approximately 1.4 million shares have traded hands today vs. average 30-day volume of 1 million shares ...

View the full article

[ImmInst]

Geron Corporation Announces Proposed Public Offering of Common Stock
Business Wire - 2 hours ago

MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today announced that it is offering to sell shares of its common stock in an underwritten public offering. Geron also expects ...

US HOT STOCKS: Geron, Spectrum Pharma Active In Late Trading - Wall Street Journal
Geron plans to sell more stock; shares slip - Forbes
RTT News- StreetInsider.com- CanadianBusiness.com

View the full article

[ImmInst]

Geron Tanks On Stock Offer Pricing
FOX Business - 10 minutes ago

BOSTON -- Geron Corp. shares dove 17% to $5.08 in early action Tuesday after the biotech firm priced a stock offering considerably below Monday's closing price. Geron said it plans to sell 17.4 ...

View the full article

[ImmInst]

Geron (GERN) NewsBite - GERN Sinks After Pricing Offering
Market Intelligence Center - 30 minutes ago

Geron (NASDAQ: GERN) opened at $5.23. So far today, the stock has hit a low of $5.05 and a high of $5.23. GERN is now trading at $5.08, down $1.04 (-17.05%). Over the last 52 weeks the stock has ...

View the full article

[ImmInst]

Geron Corp prices USD87.0m public offering of common shares
Trading Markets - 6 minutes ago

Biopharmaceuticals developer Geron Corporation (Nasdaq: GERN | PowerRating) said on Tuesday that the company has priced an underwritten public offering of 17,391,305 shares of its common stock at ...

View the full article

[ImmInst]

Is Geron the Perfect Stock?
Motley Fool - 1 hour ago

By Dan Caplinger | More Articles Everyone would love to find the perfect stock. But will you ever really find a stock that gives you everything you could possibly want? One thing's for sure: If ...

View the full article

[ImmInst]

Bernstein Liebhard LLP Announces Investigation of Geron Corporation
Business Wire - 3 hours ago

NEW YORK--(BUSINESS WIRE)--Bernstein Liebhard LLP has commenced an investigation into possible violations of the law by certain officers and directors of Geron Corporation (“Geron” or the “Company ...

View the full article

[ImmInst]

Rodman & Renshaw Tapped to Co-Manage Geron on the Pricing of Its Public Offering of Common Stock
Trading Markets - 1 hour ago

Rodman & Renshaw, a subsidiary of Rodman & Renshaw Capital Group, Inc., announced that it acted as a co-manager to Geron Corp. on the pricing of its public offering of common stock. Geron ...

View the full article

[ImmInst]

Geron Corporation Announces Closing of Its Public Offering of Common Stock
Business Wire - 34 minutes ago

MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) announced today the closing of its previously announced public offering of 17,391,305 shares of its common stock, as well as 2 ...

Geron Closes Public Offering Of 17.39 Mln Shares - Quick Facts - RTT News

View the full article